SCHEMBL14197690

SCHEMBL14197690

CC1CCN(CCNC(=O)OC(C)(C)C)C1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CACNA1H O95180 1/20 0.49
DRD2 P14416 9/20 0.47
EPHX1 P07099 1/20 0.45
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
GAA P10253 1/20 0.43
JAK2 O60674 1/20 0.43
JAK1 P23458 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
CCNT1 O60563 1/20 0.42
CDK9 P50750 1/20 0.42
ALDH1A1 P00352 1/20 0.40
TSHR P16473 1/20 0.40
CARM1 Q86X55 1/20 0.39
PRMT6 Q96LA8 1/20 0.39
PRMT1 Q99873 1/20 0.39
PRMT8 Q9NR22 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14599656 0.92 CACNA1H (0.47) CACNA1HDRD2EPHX1MEN1KMT2A
SCHEMBL16480069 0.91 CACNA1H (0.54) CACNA1HDRD2EPHX1JAK2JAK1
SCHEMBL18233674 0.86 CACNA1H (0.49) CACNA1HDRD2EPHX1MEN1KMT2A
SCHEMBL22754469 0.86 CACNA1H (0.49) CACNA1HDRD2EPHX1MEN1KMT2A
SCHEMBL18233672 0.86 CACNA1H (0.49) CACNA1HDRD2EPHX1MEN1KMT2A
SCHEMBL31420611 0.86 CACNA1H (0.49) CACNA1HDRD2EPHX1MEN1KMT2A
SCHEMBL26003617 0.85 CACNA1H (0.51) CACNA1HDRD2EPHX1MEN1KMT2A
SCHEMBL20479436 0.84 CACNA1H (0.48) CACNA1HDRD2EPHX1MEN1KMT2A
SCHEMBL28665379 0.84 CACNA1H (0.48) CACNA1HDRD2EPHX1MEN1KMT2A
SCHEMBL20480232 0.84 CACNA1H (0.48) CACNA1HDRD2EPHX1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7354946-B2 prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-08 US disclosed
US-7354946-B2 prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-08 US disclosed
US-20070027147-A1 Biarylurea derivatives MSD K.K. (JP) 2007-02-01 US disclosed
US-20070027147-A1 Biarylurea derivatives MSD K.K. (JP) 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027147-A1 Biarylurea derivatives CDK6, CDK4, CCNI CACNA1H 4772/4885DRD2 1883/4885EPHX1 2734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.